Search Result

Results for "

breast cancer (TNBC)

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (5) AMPK (1) Anaplastic lymphoma kinase (ALK) (1) Annexin A (1) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (50) Aryl Hydrocarbon Receptor (1) ATM/ATR (1) Aurora Kinase (4) Autophagy (13) Bcl-2 Family (7) c-Fms (1) c-Met/HGFR (1) c-Myc (2) Cadherin (1) Calcium Channel (1) CaMK (1) Carbonic Anhydrase (1) Casein Kinase (1) Caspase (3) Cathepsin (1) CD73 (1) CDK (8) COX (1) DNA Methyltransferase (1) DNA/RNA Synthesis (1) Drug Derivative (1) E1/E2/E3 Enzyme (2) Early 2 Factor (E2F) (1) EGFR (3) Epigenetic Reader Domain (5) ERK (3) Eukaryotic Initiation Factor (eIF) (1) FAK (3) Ferroptosis (10) FGFR (1) GLUT (1) Glutaminase (1) Glutathione Peroxidase (4) HDAC (10) HIF/HIF Prolyl-Hydroxylase (1) Histone Methyltransferase (4) HIV (3) IAP (1) IGF-1R (1) JAK (2) Kinesin (1) Lipoxygenase (1) MDM-2/p53 (4) Microtubule/Tubulin (2) Mitochondrial Metabolism (1) MMP (3) MNK (1) mTOR (2) Mucin (1) Necroptosis (1) NF-κB (1) Nuclear Hormone Receptor 4A/NR4A (1) p38 MAPK (1) PAK (1) PARP (6) Phosphatase (3) Photosensitizer (1) PI3K (2) Potassium Channel (1) PROTACs (5) Pyroptosis (1) Raf (1) Ras (2) Reactive Oxygen Species (ROS) (8) Reference Standards (2) Ribosomal S6 Kinase (RSK) (1) ROCK (1) ROR (1) SHP2 (1) Src (2) STAT (7) Survivin (1) TAM Receptor (1) TGF-β Receptor (1) Topoisomerase (1) Transmembrane Glycoprotein (1) TREM receptor (1) TROP2 (1) ULK (4) VD/VDR (1) VEGFR (4) Wnt (1) YAP (1)
By Research Areas:	Cancer (114) Infection (2) Inflammation/Immunology (6)
Click Chemistry:	Alkynes (3)

113

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Click Chemistry

Targets Recommended: BCRP BRK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-155664

GPX4-IN-6	Glutathione Peroxidase Ferroptosis	Cancer
GPX4-IN-6 (Compound C25) is a GPX4 covalent inhibitor with an IC₅₀ value of 0.13 μM. GPX4-IN-6 (Compound C25) can induce ferroptosis for the research of triple-negative breast cancer (TNBC) .

HY-148334

MS8815	PROTACs Histone Methyltransferase	Cancer
MS8815 is a selective enhancer of zeste homolog 2 (EZH2) PROTAC degrader. MS8815 has inhibition activity for EZH2 with an IC₅₀ value of 8.6 nM. MS8815 can be used for the research of triple-negative breast cancer (TNBC) .

HY-173020

W23-1006	Anaplastic lymphoma kinase (ALK) Apoptosis	Cancer
W23-1006 is a selective and covalent ALKBH5 inhibitor. W23-1006 binds to the ALKBH5 C200 residue with an IC₅₀ value of 3.848 μM. W23-1006 shows ~30- and 8-fold stronger inhibitory activity than that against FTO and ALKBH3, respectively. W23-1006 can be used for the study of triple-negative breast cancer (TNBC) .

HY-P991319

TAB-004	Mucin	Cancer
TAB-004 is a human monoclonal antibody (mAb) targeting MUC1. TAB-004 specifically recognizes tMUC1 in all major subtypes of breast cancer without affecting normal breast epithelial cells. TAB-004 can be used in triple-negative breast cancer (TNBC) research .

HY-161831

Antitumor agent-175	Reactive Oxygen Species (ROS)	Cancer
Antitumor agent-175 (Compound Ru2) is an antitumor agent with photocytotoxicity, demonstrating selective antitumor effects against triple-negative breast cancer (TNBC) cells .

HY-164550

YF438	HDAC	Cancer
YF438 is an HDAC inhibitor with effective anticancer activity both in vitro and in vivo. YF438 inhibits the growth and metastasis of triple-negative breast cancer (TNBC) cells by blocking the interaction between HDAC and MDM2, inducing the dissociation of MDM2-MDMX, and promoting the degradation of MDM2 .

HY-158439

anti-TNBC agent-7	JAK STAT	Cancer
anti-TNBC agent-7 (Compound 13c) possesses anticancer activity, serving as a molecular probe to recognize and regulate the signal transduction of the USP21/JAK2/STAT3 axis, exhibiting nanomolar-level cytotoxicity against MDA-MB-231 and HCC-1806 cancer cells, effectively combating triple-negative breast cancer (TNBC) .

HY-172177

ROCK/HDAC-IN-2	Apoptosis HDAC ROCK	Cancer
ROCK/HDAC-IN-2 (Compound C-9) is a ROCK/HDAC inhibitor, with IC₅₀ values of 0.185 µM, 0.8 µM, and 0.7 µM for HDAC6, ROCK1, and ROCK2, respectively. ROCK/HDAC-IN-2 can induce apoptosis and changes in mitochondrial membrane potential in cancer cells, demonstrating significant antitumor activity. ROCK/HDAC-IN-2 can be used in the research of pancreatic ductal adenocarcinoma (PDAC) and triple-negative breast cancer (TNBC) .

HY-175698

Ferroptosis inducer-9	Ferroptosis Microtubule/Tubulin COX Glutathione Peroxidase	Cancer
Ferroptosis inducer-9 is a ferroptosis inducer and colchicine site tubulin polymerization inhibitor. Ferroptosis inducer-9 inhibits MCF-7 cell growth with an IC₅₀ of 14 nM and inhibits [ ³H]colchicine binding. Ferroptosis inducer-9 reduces expression of GPX4 and FTH, increases COX2 and ACSL4, lowers GSH, NADP+, and NADPH levels, increases LPO, MDA, and Fe(II) levels, and decreases SOD concentrations. Ferroptosis inducer-9 demonstrates significant anti-tumor efficacy in HCT116 CRC xenograft model. Ferroptosis inducer-9 can be used for the study of triple negative breast cancer (TNBC) and colorectal cancer (CRC) .

HY-156077

anti-TNBC agent-2	Apoptosis DNA/RNA Synthesis	Cancer
anti-TNBC agent-2 (3j) an anti-Triple negative breast cancer (TNBC) purine derivative. anti-TNBC agent-2 induces MDA-MB-231 cells apoptosis, and inhibits its migration and angiogenesis. anti-TNBC agent-2 inhibits tumor growth and metastasis and reduces the expression of Ki67 and CD31 protein in TNBC xenograft models. anti-TNBC agent-2 can be used for Triple negative breast cancer (TNBC) research .

HY-155251

anti-TNBC agent-3	Apoptosis Bcl-2 Family	Cancer
anti-TNBC agent-3 (compound 3g) is an apoptosis inducer with anti-cancer cell proliferation activity. anti-TNBC agent-3 inhibits tumor growth and metastasis in triple-negative breast cancer (TNBC) xenograft models .

HY-145143

anti-TNBC agent-1	Apoptosis	Cancer
anti-TNBC agent-1 is a potent anti-triple-negative breast cancer (TNBC) agent. anti-TNBC agent-1 exhibits potent activity against different breast cancer cells with IC₅₀ values ranging from 0.20 μM to 0.27 μM. anti-TNBC agent-1 induces apoptosis of SUM-159 cells through mitochondria pathway and causes G1 phase arrest of SUM-159 cells .

HY-158108

anti-TNBC agent-6	Autophagy Ferroptosis Reactive Oxygen Species (ROS)	Cancer
anti-TNBC agent-6 (compound pt-3) is a potent anti-TNBC agent. anti-TNBC agent-6 shows cytotoxic activity. anti-TNBC agent-6 induces autophagy and ferroptosis. anti-TNBC agent-6 enhances intracellular ROS accumulatio. anti-TNBC agent-6 shows anti tumor activity and has the potential for the research of breast cancer .

HY-125465

SLLN-15	Autophagy	Cancer
SLLN-15 is an oral active, selective and potent enhancer of autophagy that activates cytostatic macroautophagy/autophagy in triple-negative breast cancer (TNBC) .

HY-175544

anti-TNBC agent-10	Drug Derivative	Cancer
anti-TNBC agent-10 is an anti-TNBC agent. anti-TNBC agent-10 shows potent anti-TNBC activity against BT549 cells (IC₅₀ = 0.018 μM) and maintains activity against MDA-MB-231 cells (IC₅₀ = 4.16 μM). anti-TNBC agent-10 9 demonstrates significant anti-tumor efficacy in mice bearing subcutaneous MDA-MB-231 TNBC xenografts. anti-TNBC agent-10 can be used for the study of triple-negative breast cancer (TNBC) .

HY-176252

CALR ligand 1	Apoptosis	Cancer
CALR ligand 1 (Compound 2a) is a calreticulin (CALR) ligand. CALR ligand 1 shows antitumor activity against triple-negative breast cancer (TNBC) cells (IC₅₀=0.1 μM). CALR ligand 1 induces intracellular calcium overloading and triggers apoptosis in TNBC cells. CALR ligand 1 is promising for research of TNBC .

HY-163381

Antiproliferative agent-48	Others	Cancer
Antiproliferative agent-48 (compound PC-A1) shows selective antiproliferative activity against triple-negative breast cancer (TNBC) cells .

HY-16916

NS1643 1 Publications Verification	Potassium Channel Autophagy	Cancer
NS1643 is a partial agonist of human ether-a-go-go-related gene (hERG) K ⁺ channels with an EC₅₀ of 10.5 μM. NS1643 inhibits the growth of breast cancer tumors in TNBC mouse models. NS1643 inhibits cell migration and invasion of breast cancer cells .

HY-173211

anti-TNBC agent-8	Photosensitizer	Cancer
anti-TNBC agent-8 (Compound TP2) is a photodynamic therapeutic agent targeting mitochondrial DNA G4 (mtG4). Under white light irradiation, its IC₅₀ against 4T1 cells is 0.42 μM. anti-TNBC agent-8 binds tightly to mtG4 and generates a large amount of reactive oxygen species (ROS) under white light irradiation, leading to the loss of mitochondrial membrane potential (MMP), a decrease in ATP production, and an increase in the ROS level. This, in turn, induces significant apoptosis in triple-negative breast cancer (TNBC) cells, exerting the activity of inhibiting tumor cell growth. anti-TNBC agent-8 can be used in the research of triple-negative breast cancer.

HY-164789

Sacituzumab tirumotecan SKB264; MK-2870	Antibody-Drug Conjugates (ADCs) TROP2	Cancer
Sacituzumab tirumotecan (SKB264/MK-2870) is a TROP2 ADC. Sacituzumab tirumotecan can be used for the research of triple-negative breast cancer (TNBC) .

HY-149847

JH530	Ras	Cancer
JH530 is an effective methuosis inducer that inhibits the triple-negative breast cancer (TNBC) cells proliferation by causing intracellular complete vacuolization. JH530 has anti-tumor activity and can be used for cancer research .

HY-176418

BBOX-IN-1	Mitochondrial Metabolism	Cancer
BBOX-IN-1 (compound 58) is a potent BBOX inhibitor with an IC₅₀ of 0.02 μM. BBOX-IN-1 can be used in the study of triple negative breast cancer (TNBC) .

HY-168106

ZMF-24	Eukaryotic Initiation Factor (eIF) Apoptosis	Cancer
ZMF-24 is an anti-triple-negative breast cancer (TNBC) agent with IC₅₀ values of 0.22 μM and 0.44 μM against TNBC proliferation in BT-549 cells and MDA-MB-231 cells, respectively. ZMF-24 inhibits Eukaryotic translation initiation factor 3 subunit D (EIF3D) that disrupts the energy supply of TNBC by inhibiting glycolysis and further induces profound TNBC apoptosis by stimulating persistent ER stress .

HY-162575

Anticancer agent 231	ERK	Cancer
Anticancer agent 231 (Compound P5) is a tyrosine protein kinase inhibitor with a IC₅₀ value of 3.95 μM. Anticancer agent 231 inhibits the cell viability, cell proliferation, cell migration and cancer dryness of triple negative breast cancer (TNBC) cells by targeting EGFR-ERK 1/2 signaling pathway, and is expected to play an important role in the field of TNBC disease therapy .

HY-172551

anti-TNBC agent-9	Apoptosis Cadherin MMP Bcl-2 Family	Cancer
anti-TNBC agent-9 (Compound 3as) is an anti-cancer agent for triple-negative breast cancer (TNBC). anti-TNBC agent-9 exhibits significant inhibitory activity against MDA-MB-453 cells with an IC₅₀ value of 8.5 μM. anti-TNBC agent-9 inhibits tumor cell migration by upregulating E-cadherin and downregulating N-cadherin, matrix metalloproteinase 2 (MMP2), and MMP9. anti-TNBC agent-9 induces apoptosis by increasing the expression of the pro-apoptotic protein BAX and decreasing the expression of the anti-apoptotic protein BCL-2, thereby inhibiting tumor cell proliferation .

HY-101923B

LYN-1604 dihydrochloride 3 Publications Verification	ULK Autophagy Apoptosis	Cancer
LYN-1604 dihydrochloride is a potent UNC-51-like kinase 1 (ULK1) activator (EC₅₀=18.94 nM) for the research of triple negative breast cancer (TNBC) .

HY-101923A

LYN-1604 hydrochloride	ULK Autophagy Apoptosis	Cancer
LYN-1604 hydrochloride is a potent UNC-51-like kinase 1 (ULK1) activator (EC₅₀=18.94 nM) for the research of triple negative breast cancer (TNBC) .

HY-101923

LYN-1604 3 Publications Verification	ULK Autophagy Apoptosis	Cancer
LYN-1604 is a potent UNC-51-like kinase 1 (ULK1) activator (EC₅₀=18.94 nM) for the research of triple negative breast cancer (TNBC) .

HY-149259

FAK-IN-9	FAK	Cancer
FAK-IN-9 (Compound 8f) is a potent and orally active FAK inhibitor with an IC₅₀ of 27.44 nM. FAK-IN-9 induces triple-negative breast cancer (TNBC) cell apoptosis .

HY-174836

ZINC000081009201	PARP	Cancer
ZINC000081009201 is a potent poly(ADP-ribose) polymerase 1 (PARP1) inhibitor with an IC₅₀ value of 1.4767 μM. ZINC000081009201 is promising for research of triple-negative breast cancer (TNBC) .

HY-122703

BETi-211	Epigenetic Reader Domain	Cancer
BETi-211 is an orally active BET inhibitor (K_i: <1 nM). BETi-211 inhibits growth of triple-negative breast cancers (TNBC) cell lines with IC₅₀ < 1 μM. BETi-211 degrades BET proteins and suppress tumor growth in xenograft breast tumors .

HY-155246

PARP1-IN-15	Apoptosis PARP	Cancer
PARP1-IN-15 (Compound 6) is a PARP1 inhibitor. PARP1-IN-15 inhibits tankyrase (TNKS) and facilitates DNA double-strand breaks damage. PARP1-IN-15 induces tumor cell apoptosis. PARP1-IN-15 has anti-cancer activity in triple-negative breast cancer (TNBC) cells and TNBC patient-derived organoids. PARP1-IN-15 can be used for research of TNBC with or without BRCA1 mutations .

HY-P991664

AG01	Src Akt ERK TAM Receptor c-Met/HGFR MMP HIF/HIF Prolyl-Hydroxylase VEGFR	Cancer
AG01 is a monoclonal antibody against progranulin (GP88). AG01 inhibits triple-negative breast cancer (TNBC) cell proliferation and migration, reduces the expression of phosphorylated protein kinases p-Src, p-AKT, and p-ERK, and reduces the expression of oncogenic proteins such as Axl, c-MET, HIF-1α, and VEGF. AG01 inhibits tumor growth and Ki67 expression in a TNBC xenograft mouse model. AG01 can be used in the research of TNBC and other cancers .

HY-155490

Nur77 antagonist 1	Nuclear Hormone Receptor 4A/NR4A Apoptosis	Cancer
Nur77 antagonist 1(Compound ja) is a selective Nur77 antagonist(K_D ^SPR_Nur77 = 91 nM). Nur77 antagonist 1 induces cancer cell apoptosis. ja displays excellent antitumor against triple-negative breast cancer (TNBC) cells .

HY-101567

BMS-986158 2 Publications Verification	Epigenetic Reader Domain	Cancer
BMS-986158 is a potent BET inhibitor with IC₅₀s of 6.6 and 5 nM in NCI-H211 small cell lung cancer (SCLC) cells and MDA-MB231 triple negative breast cancer (TNBC) cells, respectively .

HY-163535

J208	HDAC DNA Methyltransferase Apoptosis	Inflammation/Immunology Cancer
J208 is a dual inhibitor for histone deacetylase (HDAC) and DNA methyltransferase (DNMT). J208 inhibits proliferation of cancer cells, as well as the migration/invasion of triple-negative breast cancer (TNBC) cells. J208 induces apoptosis, arrests the cell cycle at G0/G1 phase. J2008 activates the innate immune signalling pathway in TNBC, by inducing the expression of endogenous retroviruses (ERVs) .

HY-163275

MDM2-IN-24	MDM-2/p53 Apoptosis	Cancer
MDM2-IN-24 (compound A3f) exhibits MDM2-inhibiting and MDMX-activating properties in triple-negative breast cancer (TNBC) cells, with apoptotic and anti-proliferative activities .

HY-168043

STAT3-IN-35	STAT	Cancer
STAT3-IN-35 is a STAT3 inhibitor that binds to SH2 domain. STAT3-IN-35 inhibits the phosphorylation of STAT3 and possesses antiproliferative activities against triple-negative breast cancer (TNBC) cell lines. STAT3-IN-35 also has a toxicity and potent antitumor activity in a TNBC xenograft model .

HY-168950

ANXA3 degrader 1	Annexin A	Cancer
ANXA3 degrader 1 (Compound 18a5) is a highly selective ANXA3 degrader with cancer cell inhibition activity. ANXA3 degrader 1 displays excellent inhibitory effect in a triple-negative breast cancer (TNBC) tumor xenograft model (TGI=96%) .

HY-118618

Eucannabinolide Hiyodorilactone A; Schkuhrin I	STAT	Cancer
Eucannabinolide is a STAT3 inhibitor. Eucannabinolide suppresses STAT3 activation at tyrosine 705, inhibiteds its translocation to nucleus, and decreases its DNA binding capacity. Eucannabinolide can be used for triple negative breast cancer (TNBC) diseases research .

HY-172966

EG31	EGFR	Cancer
EG31 is an EGFR inhibitor. EG31 effectively inhibits the proliferation of triple-negative breast cancer (TNBC) cells (GI₅₀ values of MDA-MB-231 and Hs578T cells are 498.90 nM and 740.73 nM, respectively) and induces apoptosis by inhibiting the EGFR signaling pathway. EG31 still maintains antiproliferative activity against 5-fluorouracil (5-FU)-resistant TNBC cells (GI₅₀: 519.5 nM). EG31 can be used to study TNBC resistance .

HY-161601

Ferroptosis inducer-2	Ferroptosis Reactive Oxygen Species (ROS)	Cancer
Ferroptosis inducer-2 (Compound 24) is an inducer for heme oxygenase-1 (HO-1). Ferroptosis inducer-2 exhibits anticancer activity against triple-negative breast cancer (TNBC) cells through induction of ferroptosis .

HY-168894

CT-1	Ferroptosis	Cancer
CT-1 is a derivative of Cryptotanshinone (HY-N0174). CT-1 is a ferroptosis inducer. CT-1 promotes the interaction between NCOA4 and ferritin by targeting FTH1, triggering ferritinophagy-mediated ferroptosis. CT-1 has anticancer activity against triple-negative breast cancer (TNBC). CT-1 induces ferroptosis in both N2-type tumor-associated neutrophils (TANs) and TNBC cancer cells .

HY-162477

TS-24	Cathepsin Apoptosis	Cancer
TS-24 is an inhibitor for cathepsin S, with an IC₅₀ of 4.3 μM. TS-24 exhibits radiosensitizing activity in wild type breast cancer susceptibility gene 1 (BRCA1) and in TNBC xenograft mice model, through induction of apoptosis .

HY-175805

EGFR/HDAC-IN-2	EGFR HDAC Apoptosis	Cancer
EGFR/HDAC-IN-2 (Compound 38) is dual-functional inhibitor of EGFR and HDAC3 with IC₅₀s of 20.34 and 1.09 nM for CDK9 and HDAC3, respectively. EGFR/HDAC-IN-2 has superior anti-proliferative activity against cancer cells, inhibits cell migration and induces late-stage cell apoptosis. EGFR/HDAC-IN-2 significantly inhibits triple-negative breast cancer (TNBC) tumor growth in xenograft mouse models. EGFR/HDAC-IN-2 can be used for cancers like TNBC research .

HY-22445

MY05	c-Myc	Cancer
MY05 selectively targets c-MYC in cells and disrupts MYC-MAX interaction. MY05 engages intracellular c-MYC, modulates c-MYC thermal stability, reduces c-MYC transcriptional targets, and possesses anticancer activity (TNBC, Triple-Negative Breast Cancer) .

HY-158049

Anticancer agent 199	Apoptosis Ferroptosis	Cancer
Anticancer agent 199 (Compound G-4) induces apoptosis in triple negative breast cancer (TNBC) cells via the mitochondrial pathway through inhibiting EGFR, AKT and MAPK pathways. Anticancer agent 199 also induces Ferroptosis by down-regulating LCN2. Anticancer agent 199 inhibits TNBC cell viability and migration, and induces S phase cell cycle arrest. Anticancer agent 199 is a derivate of cyclin-dependent kinase inhibitor Rocovitine .

HY-161774

ST80	CD73	Cancer
ST80 is an inhibitor for interaction of OTUD4 and CD73. ST80 decreases CD73 protein level, increases CD73 protein turnover, reduces immune evasion of tumor cells, and thus exhibits antitumor efficacy against immunosuppressive triple-negative breast cancer (TNBC) .

HY-N7694

Isotoosendanin	TGF-β Receptor JAK STAT Apoptosis	Inflammation/Immunology Cancer
Isotoosendanin is an orally active TGFβR1 inhibitor and abrogating its kinase activity (IC₅₀ = 6732 nM). Isotoosendanin inhibits the JAK/STAT3 signaling pathway by directly targeting SHP-2, enhancing its stability, and reducing its ubiquitination. Isotoosendanin inhibits TGF-β-induced reduces the migration, invasion, and metastasis in triple-negative breast cancer (TNBC) cells. Isotoosendanin exhibits anti-tumor efficacy in TNBC xenograft models and A549 xenograft tumors. Isotoosendanin exhibits significant anti-inflammatory effects in acetic acid-induced vascular permeability and λ-carrageenan-induced hind paw edema tests. Isotoosendanin can be used for the study of non-small cell lung cancer (NSCLC), TNBC and inflammation .

HY-P991620

JS006	Transmembrane Glycoprotein	Cancer
JS006 is a humanized IgG4κ monoclonal antibody inhibitor targeting TIGIT/CD155. JS006 can be used to study advanced and/or metastatic cancers with resistance to PD-1/PD-L1 inhibitor such as non-small cell lung cancer (NSCLC), advanced lymphoma and advanced/metastatic triple negative breast cancer (TNBC) .

Cat. No.	Product Name	Target	Research Area

HY-P11051

GE11, Cys Conjugated	Peptides	Cancer
GE11, Cys Conjugated is a peptide conjugate. GE11, Cys Conjugated consists of a GE11 (HY-P10128) conjugated with a GGGGC sequence. GE11, Cys Conjugated can be used for synthesis of stimuli-responsive peptide nanomaterials (SRPNs) for photoacoustic imaging and cancer therapy, such as triple-negative breast cancer (TNBC)

HY-P10947

MACTIDE-V	Epigenetic Reader Domain YAP	Cancer
MACTIDE-V is an orally active and selective peptide-drug conjugate targeting CD206. MACTIDE-V delivers Verteporfin (HY-B0146) to CD206 ⁺ tumor-associated macrophages (TAM) to inhibit the YAP/TAZ signaling pathway, prompting YAP exclusion from the nucleus, inducing TAM polarization toward an anti-tumoral phenotype with enhanced phagocytosis and antigen presentation, and boosting T cell infiltration and NK cell activity. MACTIDE-V suppresses primary tumor growth and lung metastasis in triple-negative breast cancer (TNBC) mouse models .

Cat. No.	Product Name	Target	Research Area

HY-P991319

TAB-004	Mucin	Cancer
TAB-004 is a human monoclonal antibody (mAb) targeting MUC1. TAB-004 specifically recognizes tMUC1 in all major subtypes of breast cancer without affecting normal breast epithelial cells. TAB-004 can be used in triple-negative breast cancer (TNBC) research .

HY-P991664

AG01	Src Akt ERK TAM Receptor c-Met/HGFR MMP HIF/HIF Prolyl-Hydroxylase VEGFR	Cancer
AG01 is a monoclonal antibody against progranulin (GP88). AG01 inhibits triple-negative breast cancer (TNBC) cell proliferation and migration, reduces the expression of phosphorylated protein kinases p-Src, p-AKT, and p-ERK, and reduces the expression of oncogenic proteins such as Axl, c-MET, HIF-1α, and VEGF. AG01 inhibits tumor growth and Ki67 expression in a TNBC xenograft mouse model. AG01 can be used in the research of TNBC and other cancers .

HY-P991620

JS006	Transmembrane Glycoprotein	Cancer
JS006 is a humanized IgG4κ monoclonal antibody inhibitor targeting TIGIT/CD155. JS006 can be used to study advanced and/or metastatic cancers with resistance to PD-1/PD-L1 inhibitor such as non-small cell lung cancer (NSCLC), advanced lymphoma and advanced/metastatic triple negative breast cancer (TNBC) .

HY-P991621

EOS006215 EOS-215	TREM receptor	Cancer
EOS006215 is a humanized monoclonal antibody inhibitor targeting TREM-2. EOS006215 reprograms TREM2 ⁺ macrophages, significantly blocks their pleiotropic pro-tumoral functions and overcomes resistance. EOS215 decreases metastasis burden in orthotopic 4T1 triple negative breast cancer mice model and significantly inhibits tumor growth in anti-PD-1 resistant mice model. EOS006215 can be used to study advanced malignant solid neoplasm, such as triple negative breast cancer (TNBC) .

Cat. No.	Product Name		Classification

HY-135699

TD52 2 Publications Verification		Alkynes
TD52, an Erlotinib (HY-50896) derivative, is an orally active, potent cancerous inhibitor of protein phosphatase 2A (CIP2A) inhibitor. TD52 mediates the apoptotic effect in triple-negative breast cancer (TNBC) cells via regulating the CIP2A/PP2A/p-Akt signalling pathway. TD52 indirectly reduced CIP2A by disturbing Elk1 binding to the CIP2A promoter. TD52 has less p-EGFR inhibition and has potent anti-cancer activity . TD52 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-135699A

TD52 dihydrochloride 2 Publications Verification		Alkynes
TD52 dihydrochloride, an Erlotinib (HY-50896) derivative, is an orally active, potent cancerous inhibitor of protein phosphatase 2A (CIP2A) inhibitor. TD52 dihydrochloride mediates the apoptotic effect in triple-negative breast cancer (TNBC) cells via regulating the CIP2A/PP2A/p-Akt signalling pathway. TD52 dihydrochloride indirectly reduced CIP2A by disturbing Elk1 binding to the CIP2A promoter. TD52 dihydrochloride has less p-EGFR inhibition and has potent anti-cancer activity . TD52 (dihydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-157411

anti-TNBC agent-5		Alkynes
anti-TNBC agent-5 (compound 10C) is a triple-negative breast cancer (TNBC) inhibitor with good stability and pharmacokinetic properties. anti-TNBC agent-5 exhibits antiproliferative activity against a variety of cancer cells. anti-TNBC agent-5 can also effectively inhibit TNBC lung metastasis activity in the MDA-MB-231 xenograft model. anti-TNBC agent-5 can be used in cancer research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

breast cancer (TNBC)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

NaturalProducts

Click Chemistry

Natural
Products